Gefitnib monotherapy in patients with post-operative recurrent non-small-cell lung cancer with the EGFR mutation: a Phase II study
Phase 2
- Conditions
- non small cell lung cancer with EGFR mutation
- Registration Number
- JPRN-C000000408
- Lead Sponsor
- Okayama University Cancer and Thoracic Surgery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1)EGFR mutations except exon19 deletion and exon21 mutation (L858R) or double mutation. 2)Serious infectious disease 3) Brain metastases requiring treatment 4) Serious concomitant disease 5) Ascites, pleural or pericardeal effusion requiring drainage 6)Pregnant or lactation women, or women with known or suspected pregnancy 7) Apparent ineterstitial pneumonia or pulmonary fibrosis 8) Prior treatment of gefitinib 9) Requiring emergency radiotherapy Cardiac infarction within 6 month 10)Inappropriate patients for this study judged by the physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method